Research Analysts Offer Predictions for Incyte Q2 Earnings

Incyte Co. (NASDAQ:INCY - Free Report) - William Blair boosted their Q2 2025 earnings per share estimates for shares of Incyte in a note issued to investors on Tuesday, March 18th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $1.11 per share for the quarter, up from their prior estimate of $1.10. William Blair has a "Market Perform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $4.86 per share. William Blair also issued estimates for Incyte's Q3 2025 earnings at $1.19 EPS and Q3 2026 earnings at $1.30 EPS.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%.

Several other equities research analysts have also recently weighed in on INCY. Morgan Stanley decreased their price target on Incyte from $69.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday. Stifel Nicolaus increased their target price on shares of Incyte from $75.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday, February 10th. UBS Group assumed coverage on shares of Incyte in a research report on Tuesday, December 17th. They set a "neutral" rating and a $77.00 price target for the company. Citigroup lowered their price objective on Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a research report on Tuesday, February 11th. Finally, StockNews.com cut Incyte from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, Incyte currently has a consensus rating of "Hold" and an average target price of $74.88.

Remove Ads

Incyte Stock Performance

Shares of NASDAQ:INCY traded up $0.86 during midday trading on Thursday, reaching $62.78. 2,627,264 shares of the company traded hands, compared to its average volume of 2,266,338. Incyte has a 12 month low of $50.35 and a 12 month high of $83.95. The firm's fifty day moving average price is $70.42 and its two-hundred day moving average price is $70.17. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $12.15 billion, a price-to-earnings ratio of 232.53, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76.

Hedge Funds Weigh In On Incyte

A number of hedge funds have recently modified their holdings of the company. Quintet Private Bank Europe S.A. bought a new stake in shares of Incyte in the fourth quarter worth about $26,000. Global X Japan Co. Ltd. lifted its holdings in Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 230 shares during the period. Brooklyn Investment Group purchased a new stake in Incyte in the 3rd quarter worth approximately $30,000. R Squared Ltd bought a new stake in shares of Incyte in the 4th quarter worth approximately $30,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Incyte during the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 96.97% of the company's stock.

Insider Transactions at Incyte

In related news, EVP Steven H. Stein sold 12,352 shares of Incyte stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total value of $897,866.88. Following the transaction, the executive vice president now directly owns 66,967 shares of the company's stock, valued at $4,867,831.23. The trade was a 15.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sheila A. Denton sold 14,069 shares of the stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the sale, the executive vice president now directly owns 25,848 shares of the company's stock, valued at $1,914,561.36. The trade was a 35.25 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,827 shares of company stock worth $3,322,618. Company insiders own 17.60% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.